Journal article · 2026 · Open access
Derivation and Validation of Charlson, Elixhauser and RxRisk Cost-Based Comorbidity Indices: A Register-Based Study of 350,000 Individuals Over 11 Years
PharmacoEconomics · Published 22 September 2026 · DOI 10.1007/s40273-026-01652-x
In brief
“Derivation and Validation of Charlson, Elixhauser and RxRisk Cost-Based Comorbidity Indices: A Register-Based Study of 350,000 Individuals Over 11 Years” is a 2026 journal article by Camilla Nystrand and 2 co-authors, published in PharmacoEconomics. OpenAlex counts 0 citations as of 15 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at PharmacoEconomics.
- Citations
- 0
- References
- 40
- Authors
- 3
Abstract
BACKGROUND: Comorbidity indices are widely applied to adjust for confounding in observational research. However, health economic analyses often adjust for comorbidity using mortality-based indices, despite health conditions being likely associated differently, both in terms of magnitude and direction, to resource use than to mortality. OBJECTIVE: We aimed to derive outcome-specific cost-based indices based on the Charlson, Elixhauser and RxRisk comorbidity measures, and to internally validate their performance for predicting annual healthcare costs compared with published mortality-based weights. METHODS: Using a retrospective register-based design with 11 years of data, diagnostic (International Classification of Diseases, Tenth Revision) and Anatomical Therapeutic Chemical (prescribed drugs) codes determined whether 350,000+ individuals had one or several of the disease categories defined by each comorbidity index. Outcomes were annual total healthcare costs (primary, specialised and inpatient care, prescribed drugs) and inpatient costs. Prediction models were two-part generalised linear models, adjusting for age in splines, sex and year fixed effects. Internal validation with repeated cross-validation assessed predictive performance. Calibration curves with bootstrapped variance were plotted, and improvement in prediction between mortality- and cost-based indices was assessed. RESULTS: The cost-based RxRisk index was better in terms of calibration and performed significantly better than the original mortality-based RxRisk in predicting total healthcare and inpatient costs. The mortality- and cost-based Charlson models showed inconclusive results in relation to prediction accuracy, while well calibrated. The cost-based Elixhauser index reduced prediction errors and significantly improved explained variance compared with the mortality-based index. Decile calibration plots illustrate the superior comparative advantage of RxRisk across groups, where observed versus predicted mean cost deviation averaged 7% across deciles using the cost-based RxRisk, whereas the Charlson and Elixhauser indices deviated 32-40%. CONCLUSIONS: In future research, when using a comorbidity index to adjust for confounding in cost analyses, our results suggest using the cost-based RxRisk index.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Nystrand, C., Johansson, N., & Blom, J. (2026). Derivation and Validation of Charlson, Elixhauser and RxRisk Cost-Based Comorbidity Indices: A Register-Based Study of 350,000 Individuals Over 11 Years. PharmacoEconomics. https://doi.org/10.1007/s40273-026-01652-x
MLA 9
Nystrand, Camilla, et al. “Derivation and Validation of Charlson, Elixhauser and RxRisk Cost-Based Comorbidity Indices: A Register-Based Study of 350,000 Individuals Over 11 Years.” PharmacoEconomics, 2026. https://doi.org/10.1007/s40273-026-01652-x.
Chicago
Nystrand, Camilla, Naimi Johansson, and Johannes Blom. 2026. “Derivation and Validation of Charlson, Elixhauser and RxRisk Cost-Based Comorbidity Indices: A Register-Based Study of 350,000 Individuals Over 11 Years.” PharmacoEconomics. https://doi.org/10.1007/s40273-026-01652-x.
Harvard
Nystrand, C., Johansson, N. and Blom, J. (2026) ‘Derivation and Validation of Charlson, Elixhauser and RxRisk Cost-Based Comorbidity Indices: A Register-Based Study of 350,000 Individuals Over 11 Years’, PharmacoEconomics. doi:10.1007/s40273-026-01652-x.
IEEE
C. Nystrand, N. Johansson, and J. Blom, “Derivation and Validation of Charlson, Elixhauser and RxRisk Cost-Based Comorbidity Indices: A Register-Based Study of 350,000 Individuals Over 11 Years,” PharmacoEconomics, 2026, doi: 10.1007/s40273-026-01652-x.
BibTeX
@article{nystrand2026derivation,
title = {{Derivation and Validation of Charlson, Elixhauser and RxRisk Cost-Based Comorbidity Indices: A Register-Based Study of 350,000 Individuals Over 11 Years}},
author = {Nystrand, Camilla and Johansson, Naimi and Blom, Johannes},
journal = {PharmacoEconomics},
year = {2026},
doi = {10.1007/s40273-026-01652-x},
url = {https://doi.org/10.1007/s40273-026-01652-x}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Epidemiology › Chronic Disease Management Strategies
- comorbidity index
- Charlson Comorbidity Index
- Elixhauser comorbidity index
- health care costs
- hospital costs
- cost prediction
- calibration
- confounding adjustment
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Nystrand, C., Johansson, N., & Blom, J. (2026). Derivation and Validation of Charlson, Elixhauser and RxRisk Cost-Based Comorbidity Indices: A Register-Based Study of 350,000 Individuals Over 11 Years. PharmacoEconomics. https://doi.org/10.1007/s40273-026-01652-x
How many times has this paper been cited?
0 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access: read the free full text at PharmacoEconomics.
Who wrote this paper?
Camilla Nystrand, Naimi Johansson, Johannes Blom.
What is the DOI of this paper?
10.1007/s40273-026-01652-x. The permanent link is https://doi.org/10.1007/s40273-026-01652-x.
Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.